featured
Dual Therapy Reduces Body Weight, Prediabetes, and Systolic Blood Pressure In Obese Nondiabetic Individuals
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dapagliflozin QD and Exenatide QW Dual Therapy: A 24-Week Randomized, Placebo-Controlled, Phase 2 Study Examining Effects on Bodyweight and Prediabetes In Obese Nondiabetic Adults
Diabetes Obes Metab 2016 Aug 23;[EPub Ahead of Print], P Lundkvist, C David Sjöström, S Amini, MJ Pereira, E Johnsson, JW ErikssonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.